NCT06810544 2026-04-13
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Tango Therapeutics, Inc.
Phase 1/2 Recruiting
Tango Therapeutics, Inc.
Novartis
Pfizer
Pfizer
Cancer Research UK
Institut du Cancer de Montpellier - Val d'Aurelle